USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Innovations across Biologics and Small Molecule Treatments for Chronic Diseases, Cancer and Autoimmune Disorders
20-Sep-2024
Global
Technology Research
D759-00-48-00-00
HC_2025_33862
This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) comprises insights across new developments for antibody-drug conjugates, T-cell engagers, cell and gene therapies, precision immunology and cancer care.
The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.
The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Keywords: Antibody-drug Conjugate (ADC), Calcimimetic Therapy, Chronic Kidney Disease (CKD), Precision Immuno-oncology, T-cell Engagers (TCEs), CDK2 Inhibition, Cell and Gene Therapy, Solid Cancer, Janus Kinase 2 (JAK2) Inhibitors, Myeloproliferative Neoplasms (MPNs), Small Molecule Therapies, Autoimmune Diseases
Tubulis GmbH Tubulis, Germany
Pathalys Pharma, US
Clasp Therapeutics, US
Avenzo Therapeutics, US
Obsidian Therapeutics, US
Ajax Therapeutics, US
IDRx, US
Halda Therapeutics, US
CinRx Pharma’s Value Proposition, US
Grey Wolf Therapeutics, UK
Speak directly with our analytics experts for tailored recommendations.
Recent related In Vitro Diagnostics (IVD) research
27 Aug 2026 | Global | Frost Radar
Frost Radar: AI-Powered Molecular Diagnostics, 2026
AI-powered molecular diagnostics is an emerging and moderately fragmented industry that includes molecular diagnostics companies, precision medicine platforms, sequencing specialists, AI-driven analytics providers, and disease-focused biotechnology companies. No single company has dominated, present...
25 Aug 2026 | Global | Technology Research
Breakthrough Innovations in Point-of-Care Diagnostics
This research analyzes how point-of-care (PoC) diagnostics is evolving from simple tests to decentralized, connected, and clinically actionable testing platforms across hospitals, outpatient settings, homes, and pharmacies.
The study assesses key technology shifts, including rapid molecular t...
21 Aug 2026 | Global | Technology Research
Innovations and Growth Opportunities in AI-Driven Biomanufacturing, Advanced Cell and Gene Therapies, and Precision Immunotherapy
This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping biomanufacturing, cell and gene therapy, precision immunotherapy, anti-infectives, and neurotherapeutics across oncology, infectious disease...
07 Aug 2026 | Global | Customer Research
Laboratory Product Purchasing Trends, United States and Europe, 2025–2026
Qualified respondents to this Frost & Sullivan survey were invited to participate in an online survey examining their laboratory’s product purchasing process in 2025 and expectations for 2026. Frost & Sullivan has conducted similar studies among the same target respondent groups since 2012. The su...
21 Jul 2026 | Global | Market Research
Point-of-Care Testing Market, Global, 2024–2031
The global POCT market is rapidly evolving from standalone rapid diagnostics to connected, AI-enabled clinical intelligence ecosystems that support decentralized healthcare delivery. Growth is driven by the increasing demand for faster clinical decision-making, early disease detection, personalized ...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.
The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Keywords: Antibody-drug Conjugate (ADC), Calcimimetic Therapy, Chronic Kidney Disease (CKD), Precision Immuno-oncology, T-cell Engagers (TCEs), CDK2 Inhibition, Cell and Gene Therapy, Solid Cancer, Janus Kinase 2 (JAK2) Inhibitors, Myeloproliferative Neoplasms (MPNs), Small Molecule Therapies, Autoimmune Diseases
| Deliverable Type | Technology Research |
|---|---|
| Industries | Healthcare |
| No Index | No |
| Is Prebook | No |
| Podcast | No |
| WIP Number | D759-00-48-00-00 |